Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

ClinicalTrials.gov ID: NCT00122304

Public ClinicalTrials.gov record NCT00122304. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study

Study identification

NCT ID
NCT00122304
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Enrollment
85 participants

Conditions and interventions

Interventions

  • eculizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2004
Primary completion
Not listed
Completion
Oct 31, 2006
Last update posted
Feb 20, 2007

2004 – 2006

United States locations

U.S. sites
19
U.S. states
15
U.S. cities
18
Facility City State ZIP Site status
Norris Comprehensive Cancer Center Los Angeles California 90033
Stanford University Medical Center, Division of Hematology Stanford California 94305
Hartford Hospital, Cancer Clinical Research Office Hartford Connecticut 06102
Cleveland Clinic Florida, Dept. of Clinical Research Weston Florida 33331
Indiana University Cancer Pavilion Indianapolis Indiana 46202
Johns Hopkins University Medical Center Baltimore Maryland 21205
National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda Maryland 20892
Massachusetts General Hospital Boston Massachusetts 02114
Mayo Clinic, Division of Hematology Rochester Minnesota 55905
Washington University Medical Center, Department of Internal Medicine/Division of Hematology St Louis Missouri 63110
Cooper University Hospital, Cooper Cancer Institute Voorhees Township New Jersey 08043
Roswell Park Cancer Institute Buffalo New York 14263
NYU Clinical Cancer Center New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10017
Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program Durham North Carolina 27710
The Cleveland Clinic Foundation Cleveland Ohio 44195
OHSU Center for Hematologic Malignancies Portland Oregon 97239
Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program Philadelphia Pennsylvania 19104
University of Utah, Hematology-BMT Department Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00122304, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 20, 2007 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00122304 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →